Hang Lung's NET•WORK Captures New Office Demand Wave: Landlord-Managed Space Hits 70% Occupancy
Mr. Herman Chui, Senior Director – Office, Hotel & Residence of Hang Lung Properties, said, 'Hang Lung Properties creates compelling spaces that enrich lives. NET•WORK was created to connect people and business communities, serving as a space where work and life will find the ultimate balance. Strategically located within Central's iconic Standard Chartered Bank Building, NET•WORK embodies our vision is to become a premium and leading flexible business solution provider. From eco-friendly building materials and energy saving facilities to air quality management and control, NET•WORK sets itself apart with its full commitment to sustainability and supporting our community. NET•WORK provides professional 'turn-key' solutions in which the hassle of fitting out no longer exists. While market challenges persist, Hong Kong has a key role to play, not only as an integral part of the Greater Bay Area, but also as Asia's premier financial hub. NET•WORK's achievement of strong occupancy within months since its soft launch validates the market demand for centrally located, quality and flexible business solutions. Building on the success of HANGOUT, the Company's branded multifunctional workspace in mainland China, we expect our flexible business solutions to generate even more cross-border opportunities going forward.'
The name NET•WORK represents the connection, a hub for businesses to grow, and for people to connect and be inspired. Ergonomically designed and tastefully decorated, the 13,000-square-foot NET•WORK offers bespoke, functional and sophisticated spaces ideal for fast growing enterprises, entrepreneurs, and client meetings. It features dedicated private offices and dynamic shared spaces, including 27 private offices, 212 workstations, and professional conference facilities. The space has already established itself as a nexus for high-value business connections, having hosted multiple networking events.
Members of NET•WORK can enjoy unparalleled benefits within the Hang Lung portfolio, which comprises offices and retail spaces across the border:
One membership, dual access: Privileges across NET•WORK (Hong Kong) and HANGOUT (mainland China)
Exclusive leasing offers for offices, retail spaces, and serviced apartments within Hang Lung's Hong Kong and Mainland properties
hello program benefits: Members can enjoy exclusive dining experiences at Michelin-starred restaurants within our Central portfolio, earning hello points redeemable for premium rewards through the hello Hang Lung Malls Rewards Program.
With NET•WORK, Hang Lung reaffirms its commitment to redefining workplace innovation, strengthening Hong Kong's position as Asia's premier commercial hub and setting a new benchmark for corporate excellence.
Various amenities, including the pantry (left) and wellness room (right), are thoughtfully designed to enhance the well-being of office workers
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
11 hours ago
- Malaysian Reserve
Antengene Announces Poster Presentation of ATG-022 (Claudin 18.2 ADC) at ESMO 2025
SHANGHAI and HONG KONG, July 28, 2025 /PRNewswire/ — Antengene Corporation Limited ('Antengene', SEHK: a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercialising first-in-class and/or best-in-class medicines for cancer, today announced that an abstract featuring the latest data from a Phase I/II study of the Claudin 18.2 antibody-drug conjugate (ADC), ATG-022, has been accepted for poster presentation at the 2025 European Society for Medical Oncology Annual Congress (ESMO 2025), taking place from October 17th to October 21st at the Messe Berlin in Berlin, Germany. Details of the Poster Presentation: ATG-022 (Claudin 18.2 antibody-drug conjugate)Title: Phase I/II study of Claudin 18.2 ADC ATG-022 in patients with advanced gastric/ gastroesophageal junction cancer (CLINCH)Abstract Number: 2907Presentation Number: 2113PDate: October 19, 2025 About ATG-022 ATG-022 is an antibody-drug conjugate (ADC) designed to target CLDN18.2, a member of the Claudin family of cell adhesion molecules. Under normal conditions, Claudins are located within tight junctions between cells, forming a barrier to regulate cell permeability. However, in cancer, Claudins are aberrantly expressed on the cell surface due to changes in cell polarity. CLDN18.2 is frequently overexpressed in a range of primary malignant tumors, including gastric, esophageal, cholangiocarcinoma, and pancreatic cancers. The U.S. Food and Drug Administration (FDA) has awarded Orphan Drug Designations to ATG-022, for gastric and pancreatic cancers. Data from the ongoing CLINCH study demonstrated that ATG-022 delivers robust efficacy across all levels of CLDN18.2 expression in gastric cancer patients, including those with high, low, and ultra-low expression. This broad activity positions ATG-022 as a potential market leader, capable of addressing the largest patient population with CLDN18.2-positive tumors. Furthermore, the strong efficacy observed in patients with low CLDN18.2 expression suggests promise for treating other tumor types with similar expression profiles. About Antengene Antengene Corporation Limited ('Antengene', SEHK: is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of 'Treating Patients Beyond Borders'. Antengene has built a pipeline of 9 oncology assets at various stages going from clinical to commercial, including 6 with global rights, and 3 with rights for the APAC region. To date, Antengene has obtained 31 investigational new drug (IND) approvals in the U.S. and Asia, and submitted new drug applications (NDAs) in 11 Asia Pacific markets, with the NDA for XPOVIO® (selinexor) already approved in Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand, Indonesia and Australia. Forward-looking statements The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company's Annual Report for the year ended December 31, 2024, and the documents subsequently submitted to the Hong Kong Stock Exchange. For more information, please contact: Investor Contacts: Donald LungE-mail: Mobile: +86 18420672158 PR Contacts:Peter QianE-mail: Mobile: +86 13062747000
The Sun
3 days ago
- The Sun
Shanghai Healthcare M&A Fund Takes Strategic Stake in MicroPort Scientific Corporation
HONG KONG SAR - Media OutReach Newswire - 25 July 2025 – MicroPort Scientific Corporation (Stock Code: 'MicroPort') announced that Shanghai Healthcare M&A Fund ('SHMAF'), a fund managed by SIIC Capital, a subsidiary of SIIC Group, has entered into a share purchase agreement to acquire 135,335,204 shares in MicroPort held by Otsuka Medical Devices Co., Ltd. Through this transaction, SHMAF will become a strategic shareholder in MicroPort, underscoring its role as a state-backed, professionally operated platform that is creating value and empowering, stabilizing, developing, and reshaping leading biopharmaceutical companies in China. As a homegrown Chinese innovator that has grown into a global leader in high-end medical devices, MicroPort serves as an anchor company for the industry. Its stable development is critical to both China's and the global high-end medical device supply chain. This investment reflects SHMAF's capital-driven approach to providing crucial support to domestic anchor companies, ensuring their stability and support growth of their core assets. SHMAF will support MicroPort's growth momentum and high-quality sustainable development with its expansive resources. Introducing a strategic shareholder to drive growth momentum. The transaction brings in a significant strategic shareholder for MicroPort. Leveraging its state-backed resources and industrial expertise, SHMAF will support MicroPort's development needs, core business expansion, and potential strategic mergers and acquisitions to create synergies that bolster the company's ongoing innovation and scale-up its operations. Optimizing resource allocation to unlock synergistic value. MicroPort has successfully incubated and nurtured multiple listed companies and specialized, highly influential small companies, in the process establishing a unique MicroPort ecosystem. SHMAF will leverage its capital and operational integration expertise to support MicroPort in refining its development strategy, optimizing resource allocation, and unlocking synergistic value—while fully respecting market dynamics and corporate autonomy—to further strengthen its ecosystem and competitive advantages. Enhancing ecosystem to enhance anchor company value. MicroPort's product portfolio spans across ten major verticals, including cardiovascular intervention, rhythm management, orthopaedics, neurovascular intervention, and surgical robotics, making it a core player in the high-end medical device industrial chain. SHMAF's support will not only drive MicroPort's growth, it will also accelerate its consolidation of upstream and downstream companies in Shanghai, attract highly-skilled talent, and facilitate breakthroughs in critical technologies and core components—ultimately enhancing the global competitiveness of China's high-end medical device industry. This transaction marks another significant step in SHMAF's commitment to serving biopharmaceutical anchor companies. Upholding its value investment principles, SHMAF will collaborate with MicroPort's shareholders and management team to leverage the strategic support and industrial synergies its state-backed platform offers. Together, they will reinforce MicroPort's position as China's innovation engine in high-end medical devices and contribute to the advancement of the biopharmaceutical industry.
The Sun
4 days ago
- The Sun
DBS Launches Gen AI-Powered Coaching Tool to Future Proof Its Workforce
HONG KONG SAR - Media OutReach Newswire - 24 July 2025 - DBS announced today that it is democratising coaching for its workforce with the launch of iCoach, a Generative AI-powered (Gen AI) platform developed in collaboration with Marshall Goldsmith, one of the world's top executive coaches. While most corporations reserve coaching[1] for their top executives or high potential talent, DBS believes that employees at all levels would benefit from coaching by receiving expert advice on career development as well as topical issues such as work-life balance, personal and small team leadership, or mental wellness. However, the main challenge has always been scaling coaching in an efficient and cost-effective manner – coaching is usually done on a one-to-one basis and can be costly. With the advent of Gen AI, DBS saw an opportunity to leverage the technology to overcome these challenges, enabling the bank to avail coaching to employees across its network. Lee Yan Hong, Head of Group Human Resources, DBS, said, 'As the world of work continues to evolve, building career resilience has become more important than ever. At DBS, we are committed to helping our people thrive by equipping them with future-ready capabilities through our comprehensive Triple E framework – Education, Exposure and Experience. iCoach is a powerful new addition that complements these efforts, leveraging Gen AI to offer personalised, on-demand career guidance to help every employee confidently navigate and grow in the future of work.' Betty Lam, Head of Human Resources, DBS Hong Kong, said, 'DBS continues to entrench our standing as a Responsible AI leader and bring our employees along this responsible AI journey where AI is used ethically and effectively. iCoach is a powerful tool that allows our employees to focus on personal and career growth. At the same time, we also encourage our employees to equip themselves with the necessary AI skills, which will be crucial for our collective success.' iCoach's knowledge base was developed in partnership with Marshall Goldsmith, a leading coaching expert with over four decades of experience working with top CEOs and executives, including those from Fortune 500 companies. Dr Goldsmith was inducted by Thinkers50[2] into its Hall of Fame in 2018 and is the only two-time Thinkers50 #1 Leadership Thinker in the World. He was also the inaugural winner of the Lifetime Award for Leadership by the Harvard Institute of Coaching. iCoach is always-on and available 24/7 to provide employees with just-in-time personalised career guidance. It is tailored to each employee, drawing on the context of the bank's roles, functions and internal mobility pathways to deliver relevant and actionable career advice. Data from International Coaching Federation and Better Up Career Coaching showed 70% of people in organisations who underwent coaching benefitted from improved work performance, relationships and more effective communication skills. 80% of people who received coaching reported increased self-confidence. iCoach further reinforces the bank's commitment to upskilling its employees and building career resilience, and complements other DBS initiatives including: --> iGrow, an AI / machine learning-powered platform that offers personalised career advice by matching employees to tailored learning and job opportunities based on their career and training history. --> DBS Mentoring Programme, which connects employees with leaders and peers, enabling them to gain practical guidance, career insights and support at critical points in their professional growth. --> DBS Learning Hub, which provides employees with more than 10,000 curated courses, to learn and pick up new skills. --> Be My Guest Programme, where employees have the opportunity to participate in job shadowing, workshops and projects across departments. Last year, over 4,000 such opportunities were taken up by employees. The bank's commitment to supporting employees with career development has contributed to its recognition as an employer of choice. In 2025, DBS was ranked first in TIME's 500 Best Companies in Asia Pacific, while in 2024, the bank was named among Forbes World's Best Employers. In Hong Kong, DBS Hong Kong was also recognised at the 'Bloomberg Businessweek - Financial Institutions 2025 Awards', winning the 'Training Academy – Excellence Performance' and 'Training Program of the Year – Outstanding Performance' awards. Additionally, DBS Hong Kong was honoured with the 'Employer of the Year', 'HR Team of the Year', and the 'Grand Award of Recruitment' at the Jobsdb Hong Kong HR Awards 2024/25. [1] Coaching focuses on achieving specific, short-term goals through structured guidance, while mentoring emphasises long-term personal and professional growth through a supportive relationship. For more info here. [2] Thinkers50 is the world's pre-eminent global ranking of management thinkers and has been described by The Financial Times as 'the Oscars of management thinking'. About DBS DBS is a leading financial services group in Asia with a presence in 19 markets. Headquartered and listed in Singapore, DBS is in the three key Asian axes of growth: Greater China, Southeast Asia and South Asia. The bank's 'AA-' and 'Aa1' credit ratings are among the highest in the world. Recognised for its global leadership, DBS has been named 'World's Best Bank' by Global Finance, 'World's Best Bank' by Euromoney and 'Global Bank of the Year' by The Banker. The bank is at the forefront of leveraging digital technology to shape the future of banking, having been named 'World's Best Digital Bank' by Euromoney and the world's 'Most Innovative in Digital Banking' by The Banker. In addition, DBS has been accorded the 'Safest Bank in Asia' award by Global Finance for 16 consecutive years from 2009 to 2024. DBS provides a full range of services in consumer, SME and corporate banking. As a bank born and bred in Asia, DBS understands the intricacies of doing business in the region's most dynamic markets. DBS is committed to building lasting relationships with customers, as it banks the Asian way. Through the DBS Foundation, the bank creates impact beyond banking by supporting social enterprises: businesses with a double bottom-line of profit and social and/or environmental impact. DBS Foundation also gives back to society in various ways, including equipping communities with future-ready skills and building food resilience. With its extensive network of operations in Asia and emphasis on engaging and empowering its staff, DBS presents exciting career opportunities. For more information, please visit
